Cara Therapeutics(CARA) - 2025 Q1 - Quarterly Results

Filing Information Details the general filing information for Tvardi Therapeutics, Inc., including its stock exchange listing General Information Details the Form 8-K filing, registrant Tvardi Therapeutics, Inc., its incorporation, address, and Nasdaq stock listing - Registrant is TVARDI THERAPEUTICS, INC. (formerly Cara Therapeutics, Inc.)[2][5] Stock Exchange Registration | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, par value $0.001 per share | TVRD | The Nasdaq Stock Market LLC | Results of Operations and Financial Condition Reports the company's Q1 2025 financial results, announced via a press release Q1 2025 Financial Results Announcement Tvardi Therapeutics, Inc. announced Q1 2025 financial results via a May 13, 2025 press release, furnished as Exhibit 99.1 - The Company issued a press release on May 13, 2025, announcing financial results for the fiscal quarter ended March 31, 2025[5] - The press release (Exhibit 99.1) is furnished under Item 2.02 and is not deemed 'filed' for Section 18 of the Securities Exchange Act or Sections 11 and 12(a)(2) of the Securities Act[5][6] Changes in Registrant's Certifying Accountant Outlines the dismissal of Ernst & Young LLP and the engagement of Deloitte & Touche LLP as the new independent auditor Dismissal of Independent Registered Public Accounting Firm The Audit Committee dismissed Ernst & Young LLP (EY) as the independent auditor, effective upon Q1 2025 Form 10-Q filing, with no prior disagreements or adverse opinions - Ernst & Young LLP (EY) was dismissed as the independent registered public accounting firm, effective after filing the Q1 2025 Form 10-Q[7] - EY's audit reports for 2024 and 2023 contained no adverse opinion, disclaimer, qualification, or modification[8] - No 'disagreements' or 'reportable events' occurred with EY during fiscal years 2024, 2023, and the subsequent interim period through May 12, 2025[9] Engagement of New Independent Registered Public Accounting Firm Deloitte & Touche LLP was engaged as the new independent auditor for fiscal year 2025, effective May 13, 2025, with no prior consultations on accounting principles - Deloitte & Touche LLP was engaged as the independent registered public accounting firm for fiscal year ending December 31, 2025[11] - Deloitte previously served as the independent auditor for Legacy Tvardi before the merger[11] - No consultations occurred with Deloitte regarding accounting principles, audit opinions, or any 'disagreement' or 'reportable event'[11] Financial Statements and Exhibits Lists all financial statements and exhibits filed with the Form 8-K Exhibits List Lists all exhibits filed with the Form 8-K, including a letter from Ernst & Young LLP, the financial results press release, and the Cover Page Interactive Data File Filed Exhibits | Exhibit No. | Description | | :---------- | :---------- | | 16.1 | Letter from Ernst & Young LLP to the SEC dated May 13, 2025 | | 99.1 | Press release issued on May 13, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |